Search Results - "SHAPIRO, C. L"

Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab by Olson, E.M., Abdel-Rasoul, M., Maly, J., Wu, C.S., Lin, N.U., Shapiro, C.L.

“…Central nervous system (CNS) disease as the site of first relapse after exposure to adjuvant trastuzumab has been reported. We carried out comprehensive…”
Get full text

Phase I–II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo by Ramaswamy, B., Fiskus, W., Cohen, B., Pellegrino, C., Hershman, D. L., Chuang, E., Luu, Thehang, Somlo, G., Goetz, M., Swaby, R., Shapiro, C. L., Stearns, V., Christos, P., Espinoza-Delgado, I., Bhalla, K., Sparano, J. A.

“…In preclinical models, the histone deacetylase inhibitor vorinostat sensitizes breast cancer cells to tubulin-polymerizing agents and to anti-vascular…”
Get full text

Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CALGB trial 79809 by Shapiro, C.L, Halabi, S, Hars, V, Archer, L, Weckstein, D, Kirshner, J, Sikov, W, Winer, E, Burstein, H.J, Hudis, C, Isaacs, C, Schilsky, R, Paskett, E

“…Abstract Background Chemotherapy-induced ovarian failure (CIOF) is a frequent side-effect of adjuvant chemotherapy that results in rapid bone loss. We…”
Get full text

Predictors of duloxetine response in patients with oxaliplatin‐induced painful chemotherapy‐induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial – CALGB/alliance 170601 by Smith, E.M.L., Pang, H., Ye, C., Cirrincione, C., Fleishman, S., Paskett, E.D., Ahles, T., Bressler, L.R., Le‐Lindqwister, N., Fadul, C.E., Loprinzi, C., Shapiro, C.L.

“…Duloxetine is an effective treatment for oxaliplatin‐induced painful chemotherapy‐induced peripheral neuropathy (CIPN). However, predictors of duloxetine…”
Get full text

Ovarian Failure After Adjuvant Chemotherapy Is Associated With Rapid Bone Loss in Women With Early-Stage Breast Cancer by SHAPIRO, Charles L, MANOLA, Judith, LEBOFF, Meryl

“…We sought to evaluate the effects of chemotherapy-induced ovarian failure on bone loss and markers of skeletal turnover in a prospective longitudinal study of…”
Get full text

Bigger isn't always better: the ESMO dose de-intensification guideline framework by Shapiro, C.L.

Get full text

Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients by Shapiro, C L, Hardenbergh, P H, Gelman, R, Blanks, D, Hauptman, P, Recht, A, Hayes, D F, Harris, J, Henderson, I C

“…To assess the cardiac effects of two different cumulative doses of adjuvant doxorubicin and radiation therapy (RT) in breast cancer patients. Two hundred…”
Get more information

Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC) by Mrozek, E., Kolesar, J., Young, D., Allen, J., Villalona-Calero, M., Shapiro, C.L.

“…Preclinical studies show that mitomycin-C (MMC) followed by irinotecan (CPT-11) is synergistic. Therefore, we evaluated the toxicity and efficacy of…”
Get full text

Do cell surface trafficking impairments account for variable cell surface sodium iodide symporter levels in breast cancer? by Beyer, S. J, Jimenez, R. E, Shapiro, C. L, Cho, J. Y, Jhiang, S. M

“…The Na⁺/I⁻ symporter (NIS) is a transmembrane glycoprotein that mediates iodide uptake into thyroid follicular cells and serves as the molecular basis of…”
Get full text

Phase I trial of liposomal encapsulated doxorubicin (Myocet™; D-99) and weekly docetaxel in advanced breast cancer patients by Mrózek, E., Rhoades, C. A., Allen, J., Hade, E. M., Shapiro, C. L.

“…Background:: We conducted a phase I trial to determine the safety and maximum tolerated dose (MTD) of non-pegylated liposome-encapsulated doxorubicin (Myocet™;…”
Get full text

Phase II Trial of High-Dose Liposome-Encapsulated Doxorubicin With Granulocyte Colony-Stimulating Factor in Metastatic Breast Cancer by SHAPIRO, C. L, ERVIN, T, WELLES, L, AZARNIA, N, KEATING, J, HAYES, D. F

“…PURPOSE: To estimate the toxicity and response rate of high-dose liposome-encapsulated doxorubicin (TLC D-99, Evacet, The Liposome Company Inc, Princeton, NJ)…”
Get full text

Use of breast-conserving surgery for treatment of stage I and stage II breast cancer by Guadagnoli, E, Weeks, J C, Shapiro, C L, Gurwitz, J H, Borbas, C, Soumerai, S B

“…To assess the use of breast-conserving surgery in two states reported to differ with respect to surgical treatment of breast cancer. A retrospective cohort…”
Get more information

Side Effects of Adjuvant Treatment of Breast Cancer by Shapiro, Charles L, Recht, Abram

“…Women with primary invasive breast cancer receive both local and systemic treatment. Surgery and radiation therapy are local treatments given to reduce the…”
Get full text

Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study by SAMUELS, B. L, HOLLIS, D. R, ROSNER, G. L, TRUMP, D. L, SHAPIRO, C. L, VOGELZANG, N. J, SCHILSKY, R. L

“…Multidrug resistance mediated by P-glycoprotein may be an important cause of chemotherapy failure. Renal cell carcinoma is a disease known to demonstrate a…”
Get full text

Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients by Shapiro, C L, Ayash, L, Webb, I J, Gelman, R, Keating, J, Williams, L, Demetri, G, Clark, P, Elias, A, Duggan, D, Hayes, D, Hurd, D, Henderson, I C

“…As an alternative to single-cycle cyclophosphamide, thiotepa, and carboplatin (CTCb) intensification, we evaluated the feasibility of administering one-quarter…”
Get more information

Improving discussion of surgical treatment options for patients with breast cancer : local medical opinion leaders versus audit and performance feedback by GUADAGNOLI, E, SOUMERAI, S. B, GURWITZ, J. H, BORBAS, C, SHAPIRO, C. L, WEEKS, J. C, MORRIS, N

“…We studied whether a hospital intervention utilizing medical opinion leaders and performance feedback reduced the proportion of women who reported that…”
Get full text

Treatment of metastatic breast cancer: present and future prospects by Hayes, D F, Henderson, I C, Shapiro, C L

“…Patients with recurrent breast cancer can be divided into three categories: those with locoregional recurrence, those with distant nonvisceral recurrence, and…”
Get more information

Smoking and alcohol use may be risk factors for poorer outcome in patients with clear cell renal carcinoma by Oh, William K, Manola, Judith, Renshaw, Andrew A, Brodkin, David, Loughlin, Kevin R, Richie, Jerome P, Shapiro, Charles L, Kantoff, Philip W

“…Objectives. To correlate the clinical outcomes of 148 patients with clear cell renal carcinoma treated at a single institution with a variety of other factors…”
Get full text

Radiation-associated breast cancer after Hodgkin's disease: risks and screening in perspective by Shapiro, C L, Mauch, P M

Get more information

Monitoring Therapeutic Response in Skeletal Metastases Using Dual-Energy X-Ray Absorptiometry: A Prospective Feasibility Study in Breast Cancer Patients by Shapiro, Charles L., Keating, Jennifer, Angell, Jennifer E., Janicek, Milos, Gelman, Rebecca, Hayes, Daniel, LeBoff, Meryl S.

“…Abstract Response to systemic therapy in breast cancer patients with lytic skeletal metastases manifests as a shift from increased bone resorption to new bone…”
Get full text